Relevant prognostic features of multiple myeloma and the new International Staging System

References

• Durie B G, Salmon S E. A clinical staging system for multiple myeloma: correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 1975; 36: 842–854
   PubMed Web of Science ®Google Scholar
• Salmon S E, Wampler S B. Multiple myeloma: quantitative staging and assessment of response with a programmable pocket calculator. Blood 1977; 49: 379–389
   PubMed Web of Science ®Google Scholar
• Cooper D A, Miller A C, Penny R. Biosynthesis of immunoglobulin in human immunoproliferative diseases. II. Comparison of tumour cell mass in multiple myeloma measured by synthetic rate studies with that calculated from clinical staging systems. Acta Haematol 1982; 68: 224–236
   PubMed Web of Science ®Google Scholar
• Blade J, Rosinol L. Smoldering multiple myeloma and monoclonal gammopathy of undetermined significance. Curr Treat Options Oncol 2006; 7: 237–245
   PubMedGoogle Scholar
• Johnson P W, Selby P J. The treatment of multiple myeloma: an important MRC trial. Br J Cancer 1994; 70: 781–785
   PubMed Web of Science ®Google Scholar
• MacLennan I C, Chapman C, Dunn J, Kelly K. The Medical Research Council Working Party for Leukaemia in Adults. Combined chemotherapy with ABCM versus melphalan for treatment of myelomatosis. Lancet 1992; 339: 200–205
   PubMed Web of Science ®Google Scholar
• Durie B G. The role of anatomic and functional staging in myeloma: description of Durie/Salmon plus staging system. Eur J Cancer 2006; 42: 1539–1543
   PubMed Web of Science ®Google Scholar
• Gertz M A, Lacy M Q, Dispenzieri A, Hayman S R, Kumar S K. High-dose chemotherapy with autologous hematopoietic stem cell transplantation in patients with multiple myeloma. Expert Rev Anticancer Ther 2006; 6: 343–360
   PubMed Web of Science ®Google Scholar
• Bataille R, Durie B G, Grenier J, Sany J. Prognostic factors and staging in multiple myeloma: a reappraisal. J Clin Oncol 1986; 4: 80–87
   PubMed Web of Science ®Google Scholar
• Scudla V, Indrak K. Prognostic significance of stratification systems in multiple myeloma. I. Risk categories (good and poor risk). Neoplasm 1985; 32: 469–479
   PubMed Web of Science ®Google Scholar
• Friedenberg W R, Kyle R A, Knospe W H, Bennet J M, Tsiatis A A, et al. High-dose dexamethasone for refractory or relapsing multiple myeloma. Am J Hematol 1991; 36: 171–175
   PubMed Web of Science ®Google Scholar
• Alexanian R. Ten-year survival in multiple myeloma. Arch Intern Med 1985; 145: 2073–2074
   PubMed Web of Science ®Google Scholar
• Merlini G, Gobbi P G, Ascari E. The Merlini, Waldenström, Jayakar staging system revisited. Eur J Haematol Suppl 1989; 51: 105–110
   PubMedGoogle Scholar
• Drayson M T, Chapman C E, Dunn J A, Olujohungbe A B, Maclennan I C, MRC Working Party on Leukaemia in Adults. MRC trial of alpha2b-interferon maintenance therapy in first plateau phase of multiple myeloma. Br J Haematol 1998; 101: 195–202
   PubMed Web of Science ®Google Scholar
• Gassmann W, Pralle H, Haferlach T, Pandurevic S, Graubner M, Schmitz N, et al. Staging systems for multiple myeloma: a comparison. Br J Haematol 1985; 59: 703–711
   PubMed Web of Science ®Google Scholar
• Jacobson J L, Hussein M A, Barlogie B, Durie B G, Crowley J J, Southwest Oncology Group. A new staging system for multiple myeloma patients based on the Southwest Oncology Group (SWOG) experience. Br J Haematol 2003; 122: 441–550
   PubMed Web of Science ®Google Scholar
• Salmon S E, Tesh D, Crowley J, Saeed S, Finley P, Milder M S, et al. Chemotherapy is superior to sequential hemibody irradiation for remission consolidation in multiple myeloma: A Southwest Oncology Group Study. J Clin Oncol 1990; 8: 1575–1584
   PubMed Web of Science ®Google Scholar
• Salmon S E, Crowley J J, Grogan T M, Finley P, Pugh R P, Barlogie B. Combination chemotherapy, glucocorticoids, and interferon alfa in the treatment of multiple myeloma: a Southwest Oncology Group study. J Clin Oncol 1994; 12: 2405–2414
   PubMed Web of Science ®Google Scholar
• Salmon S E, Crowley J J, Balcerzak S P, Roach R W, Taylor S A, Rivkin S E, et al. Interferon versus interferon plus prednisone remission maintenance therapy for multiple myeloma: a Southwest Oncology Group study. J Clin Oncol 1998; 16: 890–896
   PubMed Web of Science ®Google Scholar
• Berenson J R, Crowley J J, Grogan T M, Zangmeister J, Briggs A D, Mills G M, et al. Maintenance therapy with alternate-day prednisone improves survival in multiple myeloma patients. Blood 2002; 99: 3163–3168
   PubMed Web of Science ®Google Scholar
• Greipp P R, San Miguel J, Durie B G, Crowley J J, Barlogie B, Blade J, et al. International staging system for multiple myeloma. J Clin Oncol 2005; 23: 3412–3420, Epub 4 Apr 2005. Erratum in J Clin Oncol 2005;23:6281
   PubMed Web of Science ®Google Scholar
• Krejci M, Buchler T, Hajek R, Svobodnik A, Krivanova A, Pour L, et al. Prognostic factors for survival after autologous transplantation: a single centre experience in 133 multiple myeloma patients. Bone Marrow Transplant 2005; 35: 159–164
   PubMed Web of Science ®Google Scholar
• Rajkumar S V, Greipp P R. Prognostic factors in multiple myeloma. Hematol Oncol Clin North Am 1999; 13: 1295–1314
   PubMed Web of Science ®Google Scholar
• Moulopoulos L A, Maris T G, Papanikolaou N, Panagi G, Vlahos L, Dimopoulos M A. Detection of malignant bone marrow involvement with dynamic contrast-enhanced magnetic resonance imaging. Ann Oncol 2003; 14: 152–158
   PubMed Web of Science ®Google Scholar
• Lecouvet F E, Vande Berg B C, Malghem J, Maldague B E. Magnetic resonance and computed tomography imaging in multiple myeloma. Semin Musculoskelet Radiol 2001; 5: 43–55
   PubMedGoogle Scholar
• Ghanem N, Lohrmann C, Engelhardt M, Pache G, Uhl M, Saueressig U, et al. Whole-body MRI in the detection of bone marrow infiltration in patients with plasma cell neoplasms in comparison to the radiological skeletal survey. Eur Radiol 2006; 16: 1005–1014
   PubMed Web of Science ®Google Scholar
• Baur-Melnyk A, Buhmann S, Durr H R, Reiser M. Role of MRI for the diagnosis and prognosis of multiple myeloma. Eur J Radiol 2005; 55: 56–63
   PubMed Web of Science ®Google Scholar
• Moulopoulos L A, Gika D, Anagnostopoulos A, Delasalle K, Weber D, Alexanian R, et al. Prognostic significance of magnetic resonance imaging of bone marrow in previously untreated patients with multiple myeloma. Ann Oncol 2005; 16: 1824–1828
   PubMed Web of Science ®Google Scholar
• Schirrmeister H, Bommer M, Buck A K, Muller S, Messer P, Bunjes D, et al. Initial results in the assessment of multiple myeloma using 18F-FDG PET. Eur J Nucl Med Mol Imag 2002; 29: 361–366
   PubMed Web of Science ®Google Scholar
• Durie B G, Waxman A D, D'Agnolo A, Williams C M. Whole-body 18F-FDG PET identifies high-risk myeloma. J Nucl Med 2002; 43: 1457–1463
   PubMed Web of Science ®Google Scholar
• Bredella M A, Steinbach L, Caputo G, Segall G, Hawkins R. Value of FDG PET in the assessment of patients with multiple myeloma. AJR Am J Roentgenol 2005; 184: 1199–1204
   PubMed Web of Science ®Google Scholar
• Greipp P R, Raymond N M, Kyle R A, O'Fallon W M. Multiple myeloma: significance of plasmablastic subtype in morphological classification. Blood 1985; 65: 305–310
   PubMed Web of Science ®Google Scholar
• Greipp P R, Leong T, Bennett J M, Gaillard J P, Klein B, Stewart J A, et al. Plasmablastic morphology: an independent prognostic factor with clinical and laboratory correlates: Eastern Cooperative Oncology Group (ECOG) myeloma trial E9486 report by the ECOG Myeloma Laboratory Group. Blood 1998; 91: 2501–2507
   PubMed Web of Science ®Google Scholar
• Rajkumar S V, Fonseca R, Lacy M Q, Witzig T E, Therneau T M, Kyle R A, et al. Plasmablastic morphology is an independent predictor of poor survival after autologous stem-cell transplantation for multiple myeloma. J Clin Oncol 1999; 17: 1551–1557
   PubMed Web of Science ®Google Scholar
• Moreau P, Robillard N, Avet-Loiseau H, Pineau D, Morineau N, Milpied N, et al. Patients with CD45 negative multiple myeloma receiving high-dose therapy have a shorter survival than those with CD45 positive multiple myeloma. Haematologica 2004; 89: 547–551
   PubMed Web of Science ®Google Scholar
• Nowakowski G S, Witzig T E, Dingli D, Tracz M J, Gertz M A, Lacy M Q, et al. Circulating plasma cells detected by flow cytometry as a predictor of survival in 302 patients with newly diagnosed multiple myeloma. Blood 2005; 106: 2276–2279
   PubMed Web of Science ®Google Scholar
• Gertz M A, Lacy M Q, Inwards D J, Chen M G, Pineda A A, Gastineau D A, et al. Early harvest and late transplantation as an effective therapeutic strategy in multiple myeloma. Bone Marrow Transplant 1999; 23: 221–226
   PubMed Web of Science ®Google Scholar
• Rajkumar S V, Fonseca R, Lacy M Q, Witzig T E, Lust J A, Greipp P R, et al. Autologous stem cell transplantation for relapsed and primary refractory myeloma. Bone Marrow Transplant 1999; 23: 1267–1272
   PubMed Web of Science ®Google Scholar
• Gertz M A, Lacy M Q, Inwards D J, Gastineau D A, Tefferi A, Chen M G, et al. Delayed stem cell transplantation for the management of relapsed or refractory multiple myeloma. Bone Marrow Transplant 2000; 26: 45–50
   PubMed Web of Science ®Google Scholar
• Steensma D P, Gertz M A, Greipp P R, Kyle R A, Lacy M Q, Lust J A, et al. A high bone marrow plasma cell labeling index in stable plateau-phase multiple myeloma is a marker for early disease progression and death. Blood 2001; 97: 2522–2523
   PubMed Web of Science ®Google Scholar
• Alexandrakis M G, Passam F H, Kyriakou D S, Dambaki K, Niniraki M, Stathopoulos E. Ki-67 proliferation index: correlation with prognostic parameters and outcome in multiple myeloma. Am J Clin Oncol 2004; 27: 8–13
   PubMed Web of Science ®Google Scholar
• Garcia-Sanz R, Gonzalez-Fraile M I, Mateo G, Hernandez J M, Lopez-Berges M C, de las Heras N, et al. Proliferative activity of plasma cells is the most relevant prognostic factor in elderly multiple myeloma patients. Int J Cancer 2004; 112: 884–889
   PubMed Web of Science ®Google Scholar
• Tricot G, Barlogie B, Jagannath S, Bracy D, Mattox S, Vesole D H, et al. Poor prognosis in multiple myeloma is associated only with partial or complete deletions of chromosome 13 or abnormalities involving 11q and not with other karyotype abnormalities. Blood 1995; 86: 4250–4256
   PubMed Web of Science ®Google Scholar
• Tricot G, Sawyer J R, Jagannath S, Desikan K R, Siegel D, Naucke S, et al. Unique role of cytogenetics in the prognosis of patients with myeloma receiving high-dose therapy and autotransplants. J Clin Oncol 1997; 15: 2659–2666
   PubMed Web of Science ®Google Scholar
• Seong C, Delasalle K, Hayes K, Weber D, Dimopoulos M, Swantkowski J, et al. Prognostic value of cytogenetics in multiple myeloma. Br J Haematol 1998; 101: 189–194
   PubMed Web of Science ®Google Scholar
• Rajkumar S, Fonseca R, Lacy M, Witzig T, Lust J, Greipp P, et al. Abnormal cytogenetics predict poor survival after high-dose therapy and autologous blood cell transplantation in multiple myeloma. Bone Marrow Transplant 1999; 24: 497–503
   PubMed Web of Science ®Google Scholar
• Debes-Marun C S, Dewald G W, Bryant S, Picken E, Santana-Davila R, Gonzalez-Paz N, et al. Chromosome abnormalities clustering and its implications for pathogenesis and prognosis in myeloma. Leukemia 2003; 17: 427–436
   PubMed Web of Science ®Google Scholar
• Depil S, Leleu X, Micol J B, Berthon C, Lai L J, Bauters F, et al. Abnormal cytogenetics and significant bone marrow plasmacytosis are predictive of early progression and short survival in patients with low tumor mass asymptomatic multiple myeloma. Leuk Lymphoma 2004; 45: 2481–2844
   PubMed Web of Science ®Google Scholar
• Konigsberg R, Zojer N, Ackermann J, Kromer E, Kittler H, Fritz E, et al. Predictive role of interphase cytogenetics for survival of patients with multiple myeloma. J Clin Oncol 2000; 18: 804–812
   PubMed Web of Science ®Google Scholar
• Facon T, Avet-Loiseau H, Guillerm G, Moreau P, Genevieve F, Zandecki M, et al. Intergroupe Francophone du Myelome. Chromosome 13 abnormalities identified by FISH analysis and serum β2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy. Blood 2001; 97: 1566–1571
   PubMed Web of Science ®Google Scholar
• Fonseca R, Harrington D, Oken M M, Dewald G W, Bailey R J, Van Wier S A, et al. Biological and prognostic significance of interphase fluorescence in situ hybridization detection of chromosome 13 abnormalities (Δ13) in multiple myeloma: an Eastern Cooperative Oncology Group study. Cancer Res 2002; 62: 715–720
   PubMed Web of Science ®Google Scholar
• Chang H, Li D, Zhuang L, Nie E, Bouman D, Stewart A K, et al. Detection of chromosome 13q deletions and IgH translocations in patients with multiple myeloma by FISH: comparison with karyotype analysis. Leuk Lymphoma 2004; 45: 965–969
   PubMed Web of Science ®Google Scholar
• Chiecchio L, Protheroe R KM, Ibrahim A H, Cheung K L, Rudduck C, Dagrada G P, et al. on behalf of the UK Myeloma Forum. Deletion of chromosome 13 detected by conventional cytogenetics is a critical prognostic factor in myeloma. Leukemia 2006; 20: 1610–1617
   PubMed Web of Science ®Google Scholar
• Dewald G W, Therneau T, Larson D, Lee Y K, Fink S, Smoley S, et al. Relationship of patient survival and chromosome anomalies detected in metaphase and/or interphase cells at diagnosis of myeloma. Blood 2005; 106: 3553–3558
   PubMed Web of Science ®Google Scholar
• Gertz M A, Lacy M Q, Dispenzieri A, Greipp P R, Litzow M R, Henderson K J, et al. Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and −17p13 in myeloma patients treated with high-dose therapy. Blood 2005; 106: 2837–2840
   PubMed Web of Science ®Google Scholar
• Loiseau H A, Attal M, Moreau P, Charbonnel C, Garban F, Harousseau J L, et al. A comprehensive analysis of cytogenetic abnormalities in myeloma: results of the FISH analysis of 1000 patients enrolled in the IFM99 trials. Blood 2005; 106: 185a
   Web of Science ®Google Scholar
• Bergsagel P L, Kuehl W M. Molecular pathogenesis and a consequent classification of multiple myeloma. J Clin Oncol 2005; 23: 6333–6338
   PubMed Web of Science ®Google Scholar
• Shaughnessy J, Jr. Primer on medical genomics. Part IX. Scientific and clinical applications of DNA microarrays: multiple myeloma as a disease model. Mayo Clin Proc 2003; 78: 1098–1109
   PubMed Web of Science ®Google Scholar
• Claudio J O, Stewart A K. Advances in myeloma genetics and prospects for pharmacogenomic testing in multiple myeloma. Am J Pharmacogenomics 2005; 5: 35–43
   PubMedGoogle Scholar
• Stewart A K, Fonseca R. Prognostic and therapeutic significance of myeloma genetics and gene expression profiling. J Clin Oncol 2005; 23: 6339–6344
   PubMed Web of Science ®Google Scholar